Loading…

Association of anti-cyclic citrullinated peptide antibody with clinical features in patients with psoriatic arthritis

Background: Although anti-cyclic citrullinated peptide antibody (anti-CCP Ab) is reported to be found in 5-20% of patients with psoriatic arthritis (PsA), its clinical significance has not been elucidated. Objective: To clarify the association of anti-CCP Ab with clinical features in PsA. Methods: P...

Full description

Saved in:
Bibliographic Details
Published in:Modern rheumatology 2020-03, Vol.30 (2), p.365-372
Main Authors: Hagiwara, Shinya, Tsuboi, Hiroto, Terasaki, Toshihiko, Terasaki, Mayu, Toko, Hirofumi, Shimizu, Masaru, Honda, Fumika, Yagishita, Mizuki, Ohyama, Ayako, Takahashi, Hiroyuki, Yokosawa, Masahiro, Asashima, Hiromitsu, Kondo, Yuya, Matsumoto, Isao, Sumida, Takayuki
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Although anti-cyclic citrullinated peptide antibody (anti-CCP Ab) is reported to be found in 5-20% of patients with psoriatic arthritis (PsA), its clinical significance has not been elucidated. Objective: To clarify the association of anti-CCP Ab with clinical features in PsA. Methods: Patients were enrolled who fulfilled the classification criteria for psoriatic arthritis (CASPAR) criteria and visited our hospital. We retrospectively compared clinical characteristics between those who were positive and negative for anti-CCP Ab and further compared changes in disease activity in the patients treated with biological disease-modifying anti-rheumatic drugs (DMARDs). Results: We examined 41 patients (11 females), seven were anti-CCP Ab-positive and 34 were negative. Age (55.0 ± 15.1 years old) and frequency of lung involvements (71.4%) in the anti-CCP Ab-positive group were significantly higher than those (40.0 ± 16.0 and 0%, respectively) in the negative group (p  
ISSN:1439-7595
1439-7609
DOI:10.1080/14397595.2019.1586085